Stay up-to-date on the latest drugs in development.
Eosinophilic Esophagitis
MPR Weekly Dose Podcast Episode 117
The latest guidance for COVID-19 treatment Paxlovid following rebound reports; Dupixent gets a new approval; A new treatment is approved for plaque psoriasis; COVID-19 vaccine efficacy update for those aged under 5; And the latest on Monkeypox.
FDA to Review Vonoprazan for Erosive Esophagitis
Vonoprazan is an oral small molecule potassium-competitive acid blocker.
Dupixent Gets FDA Approval for Eosinophilic Esophagitis
The approval was based on efficacy and safety data from a phase 3 trial, which included two 24-week treatment periods in patients 12 years of age and older with EoE.
April 2022: Drug Pipeline Updates
The table provided is a review of notable updates that occurred in April 2022 for investigational products in development.
Dupilumab Gets Priority Review for Eosinophilic Esophagitis
Dupilumab is an interleukin-4 receptor alpha antagonist.
FDA Denies Approval of Novel Budesonide Formulation for Eosinophilic Esophagitis
The FDA stated that the application could not be approved in its present form and recommended an additional clinical study.
Tezepelumab Granted Orphan Drug Status for Eosinophilic Esophagitis
Tezepelumab is a first-in-class human monoclonal antibody that works by blocking thymic stromal lymphopoietin.
Etrasimod Granted Orphan Drug Status for Eosinophilic Esophagitis
Etrasimod is an investigational, next generation, once-daily, oral, highly selective sphingosine 1-phosphate receptor modulator.
